Prothrombin complex - Guangdong Weilun Biological
Latest Information Update: 29 Jul 2016
At a glance
- Originator Guangdong Weilun Biological
- Class Blood coagulation factors
- Mechanism of Action Blood coagulation factor replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Blood coagulation disorders
Most Recent Events
- 29 Jul 2016 Clinical trials in Coagulation disorders in China (Parenteral)